Cartalax
Also known as AED, Ala-Glu-Asp, H-Ala-Glu-Asp-OH
Cartalax is a synthetic tripeptide, Ala-Glu-Asp (AED), from the Khavinson series of short-peptide bioregulators. It has been studied in aging cell cultures, including skin fibroblasts, mesenchymal stem cells, and chondrocytes.
Preclinical research
Size
1 option- Catalog no.
- LAX20
- Specification
- 20mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
Cartalax was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Its name refers to cartilage, and in chondrocyte studies it has been compared with a cartilage-derived polypeptide complex. PubMed indexes it as the tripeptide Ala-Glu-Asp. Published studies, mostly from the developer's group, are cell-culture experiments that compare AED with related short peptides (KE, KED, AEDG) in replicatively aged cultures. Reported outcomes include changes in markers of proliferation, apoptosis, extracellular matrix remodeling, and sirtuin expression. No controlled human trials are indexed in PubMed.
Class: Synthetic tripeptide (Khavinson short-peptide bioregulator)
Mechanism of action
How the compound acts, as described in the literature.
Proposed by its developers to regulate gene expression as a short peptide able to reach the nucleus. Independent mechanistic confirmation is lacking.
In aging human skin fibroblast cultures, AED lowered MMP-9, raised the proliferation and regeneration markers Ki-67 and CD98hc, and suppressed caspase-3-dependent apoptosis.
In replicatively aged skin fibroblasts, AED increased synthesis of sirtuin-1, sirtuin-6, and collagen I.
In aging mesenchymal stem cell cultures, AED raised IGF1 and NFκB gene expression. In chondrocyte cultures, it was reported to normalize senescence-associated markers such as p16, p21, p53, TNF-α, and IL-1α.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
2016
In vitro
PMID 27259496Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro.
Lin'kova NS, et al. · Bull Exp Biol Med
Compared KE, KED, AED, and AEDG peptides in aging skin fibroblast cultures. All reduced MMP-9 and raised Ki-67 and CD98hc expression; AED and AEDG also suppressed caspase-dependent apoptosis.
2020
In vitro
PMID 33231794Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging.
Fridman NV, et al. · Bull Exp Biol Med
In human skin fibroblasts undergoing replicative aging, AED increased synthesis of sirtuin-1, sirtuin-6, and collagen I, while KE peptide mainly reduced the inflammatory factors IL-1, NF-κB, and TGF-β.
2020
In vitro
PMID 32399807Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.
Ashapkin V, et al. · Mol Biol Rep
In two aging models of human fetal bone marrow mesenchymal stem cells, AED, KED, and KE at nanomolar concentrations raised IGF1 expression 3.5- to 5.6-fold and stimulated NFκB gene expression.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
Evidence is limited to small cell- and tissue-culture studies, mostly from the developer's group, that measure marker expression rather than functional outcomes, without independent replication. No human trials or human safety data are indexed, and Cartalax is not an approved drug.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| LAX20 | Cartalax | 20mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.